Comparison of Standard Initial Dose and Reduced Initial Dose Regorafenib for Colorectal Cancer Patients: A Retrospective Cohort Study.
Masayuki NakashimaKazuki IdeKoji KawakamiPublished in: Targeted oncology (2020)
No significant difference was observed for OS between the standard group and the reduced group. However, there were fewer adverse events in the reduced group. The optimal initial dose of regorafenib should be identified in further studies.
Keyphrases